# OnCo record aprepitant (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/aprepitant/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "aprepitant" ;
  schema:name "Aprepitant (and fosaprepitant)"@en ;
  schema:alternateName "Fosaprepitant"@en, "Ivemend"@en, "Emend IV"@en, "Aponvie"@en, "Emend / Cinvanti" ;
  schema:description "Aprepitant (Emend) was the first of a new class of anti-sickness drugs. Taken with a 5-HT3 blocker and dexamethasone, it prevents the delayed nausea and vomiting that follow strongly emetogenic chemotherapy such as cisplatin."@en ;
  schema:url <https://onco.cc/drugs/aprepitant/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Aprepitant> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=aprepitant>, <https://www.cancer.gov/about-cancer/treatment/drugs/aprepitant>, <https://www.ema.europa.eu/en/medicines/human/EPAR/emend> ;
  onco:status "approved" ;
  onco:tag "nci-list", "supportive" ;
  onco:modality "Neurokinin-1 receptor antagonist (antiemetic)" ;
  onco:approval "US 2003: Prevention of acute and delayed nausea and vomiting with highly emetogenic chemotherapy (moderately emetogenic added 2005; paediatric suspension 2015)", "US 2008: Fosaprepitant intravenous prodrug for the same indications", "EU 2003: Prevention of chemotherapy-induced nausea and vomiting (Emend); Ivemend 2008" ;
  onco:related <https://onco.cc/drugs/ondansetron/>, <https://onco.cc/drugs/palonosetron/>, <https://onco.cc/drugs/dexamethasone/> ;
  onco:technologies <https://onco.cc/technologies/antiemetic-therapy/> ;
  onco:companies <https://onco.cc/companies/merck/>, <https://onco.cc/companies/heron-therapeutics/> ;
  onco:trials <https://onco.cc/trials/nct06904235/> .